Lupin rose 1.15% to Rs 851 at 14:41 IST on BSE after the company announced it has received FDA approval for Decitabine for Injection, 50 mg/vial, Single-Dose Vial.
The announcement was made during market hours today, 15 November 2018.Meanwhile, the S&P BSE Sensex was up 183.52 points, or 0.52% to 35,325.51
On the BSE, 46,000 shares were traded in the counter so far compared with average daily volumes of 77,000 shares in the past two weeks. The stock had hit a high of Rs 854.55 and a low of Rs 836 so far during the day.
Lupin announced that it has received approval for its Decitabine for Injection, 50 mg/vial, Single-Dose Vial from the United States Food and Drug Administration (FDA) to market a generic version of Otsuka Pharmaceutical Co. Ltd.'s (Otsuka) Dacogen for Injection, 50 mg/vial, Single-Dose Vial.
Lupin's Decitabine for Injection , 50 mg/vial, Single-Dose Vial is the generic version of Otsuka's Dacogen for Injection, 50 mg/vial, Single-Dose Vial. It is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Decitabine for Injection, 50 mg/vial, Single-Dose Vial had annual sales of approximately USD 135.9 million in the US (IQVIA MAT September 2018).
Lupin's consolidated net profit fell 41.24% to Rs 268.45 crore on 3.78% rise in total income to Rs 4182.09 crore in Q2 September 2018 over Q2 September 2017.
More From This Section
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Powered by Capital Market - Live News